Orphai Therapeutics Inc. ('Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for ...

Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

Fatigue scores improved significantly within a couple of years if colon cancer patients adopted an exercise regimen, ...

ICU Medical’s presentation highlighted that the company has spent more than $100m in recent years to unify its infusion pump ...

Wearable data collection devices, combined with artificial intelligence, may help clinicians detect complications earlier and improve patient care.

Nyxoah SA (NYXH) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 3:00 PM ESTCompany ParticipantsOlivier Taelman - CEO & ...

Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

A sweeping new study of psychiatric and genetic records has the potential to change treatment for millions of psychiatric ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...